Kite Pharma and The Leukemia & Lymphoma Society Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
July 01, 2015 at 08:07 AM EDT
Kite Pharma, Inc., (Nasdaq: KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to ...
